SCHIZDX
"Developing minimally invasive, tools and technologies for high throughput, low cost molecular assays for the early diagnosis of schizophrenia and other psychiatric disorders"
| Coordinatore | PSYNOVA NEUROTECH LTD
Organization address
address: "ST JOHN S INNOVATION CENTRE, COWLEY ROAD" contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://schizdx.pera.com/ |
| Totale costo | 3˙586˙932 € |
| EC contributo | 2˙757˙688 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-TP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-10-01 - 2012-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
PSYNOVA NEUROTECH LTD
Organization address
address: "ST JOHN S INNOVATION CENTRE, COWLEY ROAD" contact info |
UK (CAMBRIDGE) | coordinator | 373˙354.00 |
| 2 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 463˙290.00 |
| 3 |
MYRIAD RBM INC CORPORATION
Organization address
address: Duval Road 3300 contact info |
US (Austin) | participant | 370˙644.00 |
| 4 |
WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
Organization address
address: SCHLOSSPLATZ 2 contact info |
DE (MUENSTER) | participant | 360˙387.00 |
| 5 |
ZENTRALINSTITUT FUER SEELISCHE GESUNDHEIT
Organization address
address: Square J 5 contact info |
DE (MANNHEIM) | participant | 360˙387.00 |
| 6 |
EDI EXPERIMENTELLE UND DIAGNOSTISCHE IMMUNOLOGIE GMBH
Organization address
address: ASPENHAUSTRASSE 25 contact info |
DE (REUTLINGEN) | participant | 301˙300.00 |
| 7 |
National Institute for Bioprocessing Research and Training Ltd
Organization address
address: "Engineering Building, Belfield 125" contact info |
IE (Dublin) | participant | 206˙050.00 |
| 8 |
PERA INNOVATION LIMITED
Organization address
address: Innovation Park, Nottingham Road contact info |
UK (MELTON MOWBRAY, LEICESTERSHIRE) | participant | 175˙220.00 |
| 9 |
STORKBIO
Organization address
address: LAKI 25 contact info |
EE (TALLINN) | participant | 147˙056.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Schizophrenia and bipolar affective disorder are a major burden to affected individuals and their families and to society at large. These two severe mental illnesses affect at least 2% of the population worldwide, and whilst 50% of sufferers do not receive adequate treatment, they cost hundreds of billions in healthcare provision, treatments and lost earnings. The current diagnosis of schizophrenia (and bipolar disorder etc.) is rather subjective, not only because of the complex spectrum of symptoms and their similarity to other mental disorders, but also due to the lack of empirical disease markers. This result in long delays (up to 1-3 years) before appropriate therapeutics is prescribed to first episode schizophrenics. Early treatment is associated with greatly improved patient outcomes. There is therefore a major unmet clinical need for empirical diagnostic tests for high throughput screening of biological fluids that would enable early and accurate diagnosis of schizophrenia and related disorders. The identification of specific biomarkers for mental disorders would revolutionise the clinical management of affected individuals. Biomarkers will help in the identification of disease sub-types, aid in predicting and monitoring treatment response and compliance, and identify novel drug targets. If such biomarkers can be found in readily accessible body fluids they open up the possibility of developing new early or pre-symptomatic diagnostics and/or treatments to improve outcomes or even prevent disease. The objective of our project is to identify biomarkers of disease and develop a diagnostic assay panel/tool for the high throughput screening of biological samples for clinical research. Moreover this platform will be utilised by SMEs for drug design and development for mental disorders research into new animal models for mental dirders and identifying biomarkers for other mental disorders'